Inversion mania seems to be dying down, but med tech merger mania continues. In the latest development, Becton Dickinson announced over the weekend that it will acquire Carefusion for $12.2 billion in a bid to save costs and broaden the company's offerings to hospitals.
Chinese CRO WuXi PharmaTech has bought out XenoBiotic Laboratories, a U.S. contractor focused on early-phase research, expanding its North American presence and broadening its lab-based business.
Parexel International has bought up the U.K.'s ClinIntel, a supply chain software outfit that should fit right in with the CRO's growing technology business.
European Union regulators approved the sale of Novartis' animal health business to Eli Lilly in a deal worth $5.4 billion that is expected to propel the U.S. drugmaker closer to the front of the veterinary products line.
Alere management is in advanced talks to sell its health management business, according to Reuters. In August, the diagnostics player had said it would do so before year-end as part of an ongoing strategic review aimed at returning the company to revenue and earnings growth.
Private drugmaker Arbor Pharmaceuticals is looking for a buyer, according to Reuters, going on the market with a price tag that could exceed $1 billion.
It's a good time to be a specialty drugmaker--especially one looking to sell itself. And that's the position Arbor Pharmaceuticals is reportedly in right now.
Medtronic announced that it will fund its $43 billion acquisition of Ireland's Covidien using $16 billion in external financing instead of capital from its foreign subsidiaries. The tweak is in response to Treasury Department rules designed to discourage inversions.
Chalk up a victory for the U.S. Treasury Department, whose new rules put the kibosh on Salix Pharmaceuticals' tax inversion deal for Cosmo's Irish unit. Instead, the North Carolina company is reportedly in talks to sell itself--but to Actavis, not Allergan.
The European Union's antitrust unit is worried that Zimmer's $13.4 billion bid for crosstown rival Biomet will limit competition and wants to look into the deal further.